Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation

Transplantation

Volumn 61, Issue 8, 1996, Pages 1188-1192

  Cacciarelli, Thomas V ^b   Esquivel, Carlos O ^b   Cox, Kenneth L ^b   Hayashi, Michihiro ^b   Berquist, William E ^b   Concepcion, Waldo ^b   So, Samuel K S ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER TRANSPLANTATION; NEPHROTOXICITY; NEWBORN; ORAL DRUG ADMINISTRATION; PEDIATRIC SURGERY; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 0029958985     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199604270-00012     Document Type: Article

References (16)

1. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation: results from the U.S. Multicenter Trial. Transplantation 1995; 59: 530.
2. Jain A, Fung JJ, Venkataramanan R, et al. Comparative study of cyclosporine and FK506 dosage requirement in adult and pediatric orthotopic liver transplantation. Transplant Proc 1991; 23: 2763.
3. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
4. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
5. Nakazato P, Cox K, Concepcion W, et al. Early experience with FK 506 induction immunosuppression - suggestion for using oral FK 506. Transplant Proc 1991; 23: 3019.
6. McDiarmid SV, Colonna JO, Shaked A, Vargas JH, Ament ME, Busuttil RW. Differences in oral FK506 requirements between adult and pediatric liver transplant patients. Transplantation 1993; 55: 1328.
7. McMichael J, Irish W, McCauley J, et al. Evaluation of a novel "intelligent" dosing system for optimizing FK506 therapy. Transplant Proc 1991; 23: 2780.
8. Ho M, Jaffee R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation 1988; 45: 719.
9. Sculerati N, Stool SE. Upper airway obstruction and lymphoproliferative disease in children after liver transplantation. Transplant Proc 1988; 20: 642.
10. Breinig MK, Zitelli B, Starzl TE, Ho M. Epstein-Barr virus, cytomegalovirus, and other viral infections after liver transplantation. J Infect Dis 1987; 156: 273.
11. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524.
12. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with posttransplantation lymphoproliferative disease. N Engl J Med 1992; 327: 1710.
13. McCauley J, Takaya S, Fung JJ, et al. The question of FK506 nephrotoxicity after liver transplantation. Transplant Proc 1991; 23: 1444.
14. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23: 3105.
15. Johnson MC, So S, Marsh JW, Murphy AM. QT prolongation and torsades de pointes after administration of FK506. Transplantation 1992; 53: 929.
16. Atkinson P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345: 894.